問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Thoracic Medicine

更新時間：2023-09-19

邱昭華Chiu, Chao-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • chaohuachiu@tmu.edu.tw

Recruiting Trial

103Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱昭華

List

195Cases

2022-04-01 - 2027-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2028-09-01

Phase I

Completed
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

  • Condition/Disease

    Metastatic Solid Tumors

  • Test Drug

    table

Participate Sites
4Sites

Recruiting4Sites

2018-06-01 - 2020-05-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-11-03 - 2025-08-25

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-05-01 - 2030-12-01

Phase III

Active
Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

  • Condition/Disease

    Locally advanced or metastatic RAS-mutant non–small cell lung cancer (NSCLC)

  • Test Drug

    Docetaxel AqVida 20 mg/ml concentrate for solution for infusion

Participate Sites
5Sites

Recruiting5Sites

2021-05-31 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2016-07-30 - 2025-05-13

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-09-22 - 2029-03-18

Phase II

Active
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

  • Condition/Disease

    Metastatic Non-Small Cell Lung Cancer (LIBRA)

  • Test Drug

    Injection

Participate Sites
9Sites

Recruiting9Sites

2024-01-22 - 2027-05-27

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Condition/Disease

    Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2022-12-23 - 2026-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

1 6 7 8 9 10 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB